Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):56–60. doi: 10.1038/bjc.1990.12

Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret.

J Hawthorn 1, D Cunningham 1
PMCID: PMC1971346  PMID: 2137008

Abstract

A new group of selective 5HT3 antagonists are proving to be effective anti-emetics for cytotoxic and radiation induced vomiting in both animal models and man. Current anti-emetic regimens often benefit from combination therapy, in particular the efficacy of metoclopramide (which can be a weak 5HT3 antagonist), can be improved by combination with dexamethasone, another anti-emetic. Hence it was of interest to evaluate whether a 5HT3 receptor antagonist GR38032F could be improved by combination with dexamethasone. Vomiting induced by cyclophosphamide in the ferret was observed after pre-treatment with dexamethasone alone or in combination with GR38032F. Animals were also observed for signs of 'nausea'. Dexamethasone alone proved a weak anti-emetic in this system but did have significant effects on 'nausea'. GR38032F has previously been shown to be capable of totally controlling emesis due to cyclophosphamide in the ferret. Here a dose of GR38032F that is not 100% effective was employed; this was shown to have effects on 'nausea' but most interestingly its anti-emetic action was increased by combination with dexamethasone. This may be important for the minority of patients whose vomiting is not completely controlled by GR38032F alone.

Full text

PDF
56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aapro M. S., Alberts D. S. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol. 1981;7(1):11–14. doi: 10.1007/BF00258206. [DOI] [PubMed] [Google Scholar]
  2. Allan S. G., Cornbleet M. A., Warrington P. S., Golland I. M., Leonard R. C., Smyth J. N. Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J (Clin Res Ed) 1984 Oct 6;289(6449):878–879. doi: 10.1136/bmj.289.6449.878-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andrews P. L., Hawthorn J. Evidence for an extra-abdominal site of action for the 5-HT3 receptor antagonist BRL24924 in the inhibition of radiation-evoked emesis in the ferret. Neuropharmacology. 1987 Sep;26(9):1367–1370. doi: 10.1016/0028-3908(87)90100-6. [DOI] [PubMed] [Google Scholar]
  4. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bruera E. D., Roca E., Cedaro L., Chacón R., Estévez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 1983 Apr;67(4):381–383. [PubMed] [Google Scholar]
  6. Carmichael J., Cantwell B. M., Edwards C. M., Rapeport W. G., Harris A. L. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin. BMJ. 1988 Jul 9;297(6641):110–111. doi: 10.1136/bmj.297.6641.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carpenter D. O., Briggs D. B., Knox A. P., Strominger N. L. Radiation-induced emesis in the dog: effects of lesions and drugs. Radiat Res. 1986 Dec;108(3):307–316. [PubMed] [Google Scholar]
  8. Coates A., Abraham S., Kaye S. B., Sowerbutts T., Frewin C., Fox R. M., Tattersall M. H. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983 Feb;19(2):203–208. doi: 10.1016/0277-5379(83)90418-2. [DOI] [PubMed] [Google Scholar]
  9. Costall B., Domeney A. M., Naylor R. J., Tattersall F. D. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology. 1986 Aug;25(8):959–961. doi: 10.1016/0028-3908(86)90030-4. [DOI] [PubMed] [Google Scholar]
  10. Cunningham D., Hawthorn J., Pople A., Gazet J. C., Ford H. T., Challoner T., Coombes R. C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987 Jun 27;1(8548):1461–1463. doi: 10.1016/s0140-6736(87)92208-2. [DOI] [PubMed] [Google Scholar]
  11. Cunningham D., Turner A., Hawthorn J., Rosin R. D. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet. 1989 Jun 10;1(8650):1323–1323. doi: 10.1016/s0140-6736(89)92711-6. [DOI] [PubMed] [Google Scholar]
  12. Florczyk A. P., Schurig J. E., Bradner W. T. Cisplatin-induced emesis in the Ferret: a new animal model. Cancer Treat Rep. 1982 Jan;66(1):187–189. [PubMed] [Google Scholar]
  13. Fozard J. R. Neuronal 5-HT receptors in the periphery. Neuropharmacology. 1984 Dec;23(12B):1473–1486. doi: 10.1016/0028-3908(84)90091-1. [DOI] [PubMed] [Google Scholar]
  14. Gralla R. J., Itri L. M., Pisko S. E., Squillante A. E., Kelsen D. P., Braun D. W., Jr, Bordin L. A., Braun T. J., Young C. W. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981 Oct 15;305(16):905–909. doi: 10.1056/NEJM198110153051601. [DOI] [PubMed] [Google Scholar]
  15. Hawthorn J., Ostler K. J., Andrews P. L. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol. 1988 Jan;73(1):7–21. doi: 10.1113/expphysiol.1988.sp003124. [DOI] [PubMed] [Google Scholar]
  16. King G. L. Characterization of radiation-induced emesis in the ferret. Radiat Res. 1988 Jun;114(3):599–612. [PubMed] [Google Scholar]
  17. Leibundgut U., Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet. 1987 May 23;1(8543):1198–1198. doi: 10.1016/s0140-6736(87)92159-3. [DOI] [PubMed] [Google Scholar]
  18. Livrea P., Trojano M., Simone I. L., Zimatore G. B., Logroscino G. C., Pisicchio L., Lojacono G., Colella R., Ceci A. Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. J Neurol. 1985;231(6):336–339. doi: 10.1007/BF00313712. [DOI] [PubMed] [Google Scholar]
  19. Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Palmer M. C., Colls B. M. Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam. Cancer Chemother Pharmacol. 1987;19(4):331–334. doi: 10.1007/BF00261483. [DOI] [PubMed] [Google Scholar]
  21. Pollera C. F., Nardi M., Marolla P., Carlini P. A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Cancer Chemother Pharmacol. 1987;19(4):335–338. doi: 10.1007/BF00261484. [DOI] [PubMed] [Google Scholar]
  22. Rich W. M., Abdulhayoglu G., DiSaia P. J. Methylprednisolone as an antiemetic during cancer chemotherapy--a pilot study. Gynecol Oncol. 1980 Apr;9(2):193–198. doi: 10.1016/0090-8258(80)90027-x. [DOI] [PubMed] [Google Scholar]
  23. Richardson B. P., Engel G., Donatsch P., Stadler P. A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature. 1985 Jul 11;316(6024):126–131. doi: 10.1038/316126a0. [DOI] [PubMed] [Google Scholar]
  24. Stables R., Andrews P. L., Bailey H. E., Costall B., Gunning S. J., Hawthorn J., Naylor R. J., Tyers M. B. Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev. 1987 Dec;14(3-4):333–336. doi: 10.1016/0305-7372(87)90026-0. [DOI] [PubMed] [Google Scholar]
  25. Stryker J. A., Demers L. M., Mortel R. Prophylactic ibuprofen administration during pelvic irradiation. Int J Radiat Oncol Biol Phys. 1979 Nov-Dec;5(11-12):2049–2052. doi: 10.1016/0360-3016(79)90958-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES